Strong association of interleukin-6-174G/C promoter single nucleotide polymorphism with a decreased risk of colorectal cancer in ethnic Kashmiri population: A case control study

被引:17
作者
Banday, Mujeeb Zafar [1 ]
Balkhi, Henah Mehraj [1 ]
Sameer, Aga Syed [2 ]
Chowdri, Nissar A. [3 ]
Haq, Ehtishamul [1 ]
机构
[1] Univ Kashmir, Dept Biotechnol, Srinagar, Jammu & Kashmir, India
[2] King Saud Bin Abdulaziz Univ Hlth Sci, Dept Basic Med Sci, Coll Med, Jeddah, Saudi Arabia
[3] Sherikashmir Inst Med Sci, Dept Surg, Srinagar, Jammu & Kashmir, India
关键词
Colorectal cancer; Kashmir; case control study; interleukin-6; polymorphism; single nucleotide polymorphism; NF-KAPPA-B; PROGNOSTIC-SIGNIFICANCE; GENOTYPING ERRORS; COMMON POLYMORPHISMS; GENE POLYMORPHISMS; SERUM-LEVEL; IL-6; INFLAMMATION; GENDER; COLON;
D O I
10.1177/1010428317695940
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic inflammation increases the risk of development of various cancers, including colorectal cancer. Interleukin-6 has been described as a key regulator of colorectal cancer development and is important in the process of colorectal tumorigenesis largely through the regulation of tumor-promoting inflammation. Several studies have reported the association of various polymorphisms in human interleukin-6 gene including IL-6 -174G/C single nucleotide polymorphism with various cancers, including colorectal cancer, but the results are mixed and inconclusive. The aim of this study was to analyze the association of IL-6 -174G/C promoter single nucleotide polymorphism with colorectal cancer risk and also to evaluate the modifying effects of possible IL-6 -174G/C single nucleotide polymorphism genotypes on different risk factors of colorectal cancer or the reciprocal effect in ethnic Kashmiri population through a case control setup. The genotype frequencies of IL-6 -174G/C promoter single nucleotide polymorphism were compared between 142 colorectal cancer patients and 184 individually matched healthy controls by using polymerase chain reaction-restriction fragment length polymorphism method. The association between the IL-6 -174G/C single nucleotide polymorphism and colorectal cancer risk was examined through conditional logistic regression models adjusted for multiple possible confounding (third) variables. The possible effect measure modification of the association between the relevant single nucleotide polymorphism genotypes and colorectal cancer risk by various colorectal cancer risk factors including age, gender, and smoking status was also evaluated. Furthermore, the associations between these single nucleotide polymorphisms and various clinicopathological parameters, demographic variables, and environmental factors within the case group subjects with regard to colorectal cancer risk were also analyzed. The overall association between the IL-6 -174G/C single nucleotide polymorphism and the modulation of colorectal cancer risk was found to be highly significant (p = 0.001). The variant genotype (CC) was significantly associated with a decreased risk of colorectal cancer (odds ratio, 0.15 (95% confidence interval, 0.04-0.54); p = 0.004). Furthermore, the less common IL-6-174C allele was associated with a decreased risk of colorectal cancer (odds ratio, 0.49 (95% confidence interval, 0.33-0.73); p = 0.0006). The combined variant genotype (GC + CC) was also significantly associated with a decreased risk of colorectal cancer (odds ratio, 0.54 (95% confidence interval, 0.33-0.89); p = 0.015). This study demonstrates that there is a strong and highly significant association between the IL-6 -174G/C promoter single nucleotide polymorphism and a decreased risk of colorectal cancer in ethnic Kashmiri population. However, in order to substantiate our findings, this study needs to be replicated with larger sample size and with other ethnically defined populations with comparable colorectal cancer incidence.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 75 条
  • [1] Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins
    Abuli, Anna
    Fernandez-Rozadilla, Ceres
    Alonso-Espinaco, Virginia
    Munoz, Jenifer
    Gonzalo, Victoria
    Bessa, Xavier
    Gonzalez, Dolors
    Clofent, Joan
    Cubiella, Joaquin
    Morillas, Juan D.
    Rigau, Joaquim
    Latorre, Mercedes
    Fernandez-Banares, Fernando
    Pena, Elena
    Riestra, Sabino
    Paya, Artemio
    Jover, Rodrigo
    Xicola, Rosa M.
    Llor, Xavier
    Carvajal-Carmona, Luis
    Villanueva, Cristina M.
    Moreno, Victor
    Pique, Josep M.
    Carracedo, Angel
    Castells, Antoni
    Andreu, Montserrat
    Ruiz-Ponte, Clara
    Castellvi-Bel, Sergi
    [J]. BMC CANCER, 2011, 11
  • [2] INTERLEUKIN-6 IN BIOLOGY AND MEDICINE
    AKIRA, S
    TAGA, T
    KISHIMOTO, T
    [J]. ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 : 1 - 78
  • [3] American Cancer Society, 2016, CANC FACTS FIG 2016
  • [4] [Anonymous], 2018, ANTI-CANCER DRUG, DOI [DOI 10.3322/caac.20115, DOI 10.1097/CAD.0000000000000617]
  • [5] New therapeutic strategies for treatment of inflammatory bowel disease
    Atreya, R.
    Neurath, M. F.
    [J]. MUCOSAL IMMUNOLOGY, 2008, 1 (03) : 175 - 182
  • [6] Ayub SG, 2011, ASIAN PAC J CANCER P, V12, P1867
  • [7] Relationship between Single Nucleotide Polymorphisms in-174G/C and-634C/G Promoter Region of Interleukin-6 and Prostate Cancer
    Bao, Shixin
    Yang, Weimin
    Zhou, Siwei
    Ye, Zhangqun
    [J]. JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2008, 28 (06) : 693 - 696
  • [8] Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone
    Beagley, KW
    Gockel, CM
    [J]. FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY, 2003, 38 (01): : 13 - 22
  • [9] Belluco C, 2003, CLIN CANCER RES, V9, P2173
  • [10] The discovery of how gender influences age immunological mechanisms in health and disease, and the identification of ageing gender-specific biomarkers, could lead to specifically tailored treatment and ultimately improve therapeutic success rates
    Berghella, Anna Maria
    Contasta, Ida
    Del Beato, Tiziana
    Pellegrini, Patrizia
    [J]. IMMUNITY & AGEING, 2012, 9